Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of sacituzumab tirumotecan versus nonplatinum chemotherapy in previously treated advanced urothelial cancer
NL-OMON61055Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in transitional cell carcinoma (TCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Started Apr 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON61055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61055.